A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the efficacy of BKM120 (parameter: Overall Response Rate) in all patients and patients with an activated PI3K pathway status
24 months
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CBKM120C2201
NCT01289041
February 2011
May 2013
Name | Location |
---|---|
Cancer Care Northwest CC Northwest- Spokane South(3) | Spokane, Washington 99202 |
Highlands Oncology Group Dept of Highlands Oncology Grp | Fayetteville, Arkansas 72703 |
Sarah Cannon Research Institute SCRI (2) | Chattanooga, Tennessee 37404 |
Texas Oncology, P.A. Austin | Bedford, Texas 76022 |
South Texas Oncology and Hematology, PA South Tex Onc | San Antonio, Texas 78258 |
St. Joseph's Hospital & Medical Center St Jospeh's | Phoenix, Arizona 85013 |
Morristown Memorial Hospital MMH | Morristown, New Jersey 07962 |
Carolinas HealthCare Systems Blumenthal Cancer Center | Charlotte, North Carolina 28207 |
University of Oklahoma Health Sciences Center OU Health | Oklahoma City, Oklahoma 73104 |